Epidemiologic evidence supported an inverse association between HDL (high-density
lipoprotein) cholesterol (HDL-C) levels and atherosclerotic cardiovascular disease …

Coronary heart disease (CHD) is a major cause of morbidity and mortality worldwide.
Elevated low density lipoprotein-cholesterol (LDL-C) and reduced high density lipoprotein …

There is robust epidemiological evidence dating back to the original Framingham Heart
Study from 1977 that indicates an important inverse relationship between high-density …

Reduction in low-density lipoprotein cholesterol (LDL-C) levels has been associated with a
25–30% reduction in cardiovascular disease risk. However, there still remains a significant …

Numerous epidemiological studies have identified high-density lipoprotein cholesterol
(HDL) to be an independent risk factor for coronary heart disease (CHD). HDL is an …

Trials of lipid lowering by various methods have clearly demonstrated the benefits, clinically
and angiographically. Evidence of slowed arterial disease progression and even regression …

The substantial residual cardiovascular events present in statin-treated patients provide a
challenge to researchers in the cardiovascular field to develop additional therapeutic …

Low-density lipoprotein (LDL)-apheresis is a Food and Drug Administration–approved
treatment for patients with homozygous familial hypercholesterolemia (FH) or severe …

Atherosclerosis is the leading cause of death in developed countries. High density
lipoproteins (HDL) cholesterol level correlates inversely with the risk of cardiovascular …

Raising the level of high-density lipoprotein (HDL) cholesterol has been proposed as a
potential therapeutic strategy to reduce cardiovascular risk, largely based on the …